Statistical issues in implementing the marker method

Growth Hormone and IGF Research

Volumn 19, Issue 4, 2009, Pages 361-365

  Bassett, E Eryl ^a   Erotokritou Mulligan, Ioulietta ^b  

^a UNIVERSITY OF KENT   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Growth hormone; Harmonisation; Measurement uncertainty; Statistical analysis

Indexed keywords

HUMAN GROWTH HORMONE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SOMATOMEDIN C;

ALGORITHM; ARTICLE; ATHLETE; BLOOD SAMPLING; CALIBRATION; DOPING; FALSE POSITIVE RESULT; HORMONE DETERMINATION; HUMAN; MEASUREMENT ERROR; NORMAL VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SPORT INJURY; STANDARDIZATION; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; ALGORITHMS; ATHLETES; BIOLOGICAL MARKERS; CHILD; DATA INTERPRETATION, STATISTICAL; DOPING IN SPORTS; FEMALE; HUMAN GROWTH HORMONE; HUMANS; MALE; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS; SUBSTANCE ABUSE DETECTION;

EID: 67651152743     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.04.024     Document Type: Article

References (10)

1. Powrie J.K., Bassett E.E., Rosen T., et al. Detection of growth hormone abuse in sport. Growth Horm. IGF Res. 17 (2007) 220-226
2. Brown P.J., Kenward M.G., and Bassett E.E. Bayesian discrimination with longitudinal data. Biostatistics 2 (2001) 417-432
3. Healy M.L., Dall R., Gibney J., et al. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the post competition setting. J. Clin. Endocrinol. Metab. 90 (2005) 641-649
4. Kniess A., Ziegler E., Kratzsch J., Thieme D., and Muller R.K. Potential parameters for the detection of hGH doping. Anal. Bioanal. Chem. 376 (2003) 696-700
5. Erotokritou-Mulligan I., Bassett E.E., Kniess A., Sonksen P.H., and Holt R.I.G. Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. Growth Horm. IGF Res. 17 (2007) 416-423
6. Goodall I. HbA1c standardisation destination - global IFCC standardisation. How, why, where and when - a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes. Clin. Biochem. Rev. 26 (2005) 5-19
7. Abellan R., Ventura R., Pichini S., et al. Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport. Clin. Chem. Lab. Med. 43 (2005) 75-85
8. Ivan D., Brabant G., and Kann P.H. German KIMS Board, applicability of recently established reference values for serum insulin-like growth factor 1: a comparison of two assays - an (automated) chemiluminescence immunoassay and an enzyme-linked immunosorbent assay. Clin. Lab. 51 (2005) 381-387
9. Rinaldi S., Kaaks R., Zeleniuch-Jacquotte A., et al. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol. Biomark. Prev. 14 (2005) 48-52
10. Massart C., and Poirier J.Y. Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin. Chim. Acta 373 (2006) 176-179